Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Beta-secretase 1 Stories

2014-03-05 10:35:00

Stem cells from patients offer model and drug-discovery platform for early-onset form of disease Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells. This may also make it possible to develop therapies far more quickly and accurately than before. The research, led by...

2014-02-20 08:31:52

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase...

2013-11-04 08:26:12

NEW YORK, NY, Nov. 4, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) announces that issue 38 (2013) of the international scientific journal Neuropsychopharmacology contains a report demonstrating that ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta ("amyloid") proteins and memory deficit in a mouse model of Alzheimer's disease (AD). A reduction in these two main hallmarks of Alzheimer's has the potential to stop, slow or reverse...

2013-08-08 09:39:19

Though one might think the brains of people who develop Alzheimer's disease (AD) possess building blocks of the disease absent in healthy brains, for most sufferers, this is not true. Every human brain contains the ingredients necessary to spark AD, but while an estimated 5 million Americans have AD – a number projected to triple by 2050 – the vast majority of people do not and will not develop the devastating neurological condition. For researchers like...

2013-07-14 08:21:35

BOSTON, July 14, 2013 /PRNewswire-USNewswire/ -- Results of four research trials investigating new targets for therapies in Alzheimer's disease, and incorporating novel approaches to participant identification and selection, were reported today at the Alzheimer's Association International Conference® 2013 (AAIC® 2013) in Boston. The trials involve four compounds that target physical changes in the brain associated with the development and progression of Alzheimer's disease. Two...

2013-07-12 12:25:54

BOSTON, July 12, 2013 /PRNewswire-USNewswire/ -- Three studies reported at the Alzheimer's Association International Conference® 2013 (AAIC® 2013) demonstrate the vitality and diversity of Alzheimer's disease research being conducted in Boston, the host city for this year's conference. The three research reports cover: Early-stage drug development for new compounds to reduce beta-amyloid. Identifying genes that impact the rate of decline in Alzheimer's disease. Early...

2013-06-24 10:37:13

Researchers in Berlin and Munich, Germany and Oxford, United Kingdom, have revealed that a protein well known for its role in Alzheimer's disease controls spindle development in muscle and leads to impaired movement in mice when the protein is absent or treated with inhibitors. The results, which are published in The EMBO Journal, suggest that drugs under development to target the beta-secretase-1 protein, which may be potential treatments for Alzheimer's disease, might produce unwanted side...

Alzheimer's Disease Drug Stopped Mid-Trial
2013-06-17 05:08:38

Lee Rannals for redOrbit.com - Your Universe Online Eli Lilly & Co has ended a clinical trial for an Alzheimer's disease drug during the middle of the study after patients showed abnormal liver biochemical tests. The company announced last week that it would be putting a halt to its LY2886721 drug trial. LY2886721, the code-name for the drug, was designed to inhibit beta secretase, which contributes to the buildup of amyloid plaque in the brain that is believed to cause Alzheimer's....

2013-06-13 16:27:02

Decision does not impact other Lilly Alzheimer's compounds in development INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have...

2013-05-29 10:13:32

Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease. The team used a new chemical method to produce a library of sugars, called heparan sulphates, which are known to control the formation of the proteins in the brain that cause memory loss. Heparan sulphates are found in nearly every cell of the body, and are similar to the natural...